News

Exelixis (NasdaqGS:EXEL) recently announced positive topline results from the STELLAR-303 Phase 3 trial, highlighting the ...
EXEL jumps 7.4% as STELLAR-303 trial hits key survival goal in colorectal cancer, boosting hopes for an approval of ...